Golan, Talia

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science

Gut microbiota and healthBacterial Cancer Therapy

Cited by 2,464

Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine

PARP inhibition in cancer therapyPancreatic and Hepatic Oncology Research

Cited by 2,302

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

Geller, L. T., Barzily-Rokni, M., Danino, T., Jonas, O. H., Shental, N., Nejman, D., Gavert, N., Zwang, Y., Cooper, Z. A., Shee, K., et al. (2017) · Science

Pancreatic and Hepatic Oncology ResearchBacterial Cancer Therapy

Cited by 1,817

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

Fuchs, C. S., Doi, T., Jang, R. W., Muro, K., Satoh, T., Machado, M., Sun, W., Jalal, S. I., Shah, M. A., Metges, J.-P., et al. (2018) · JAMA Oncology

Cancer Immunotherapy and BiomarkersGastric Cancer Management and Outcomes

Cited by 1,784

Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours

Gavish, A., Tyler, M., Greenwald, A. C., Hoefflin, R., Simkin, D., Tschernichovsky, R., Galili Darnell, N., Somech, E., Barbolin, C., Antman, T., et al. (2023) · Nature

Single-cell and spatial transcriptomicsCancer Genomics and Diagnostics

Cited by 556

Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers

Singhi, A. D., George, B., Greenbowe, J. R., Chung, J., Suh, J., Maitra, A., Klempner, S. J., Hendifar, A., Milind, J. M., Golan, T., et al. (2019) · Gastroenterology

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 348

RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

Golan, T., Khvalevsky, E. Z., Hubert, A., Gabai, R. M., Hen, N., Segal, A., Domb, A., Harari, G., David, E. B., Raskin, S., et al. (2015) · Oncotarget

Pancreatic and Hepatic Oncology ResearchRNA Interference and Gene Delivery

Cited by 336

Mutant KRAS is a druggable target for pancreatic cancer

Zorde Khvalevsky, E., Gabai, R., Rachmut, I. H., Horwitz, E., Brunschwig, Z., Orbach, A., Shemi, A., Golan, T., Domb, A. J., Yavin, E., et al. (2013) · Proceedings of the National Academy of Sciences

RNA Interference and Gene DeliveryPancreatic and Hepatic Oncology Research

Cited by 295

Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

Harrington, K. J., Brody, J., Ingham, M., Strauss, J., Cemerski, S., Wang, M., Tse, A., Khilnani, A., Marabelle, A., & Golan, T. (2018) · Annals of Oncology

interferon and immune responsesCancer Immunotherapy and Biomarkers

Cited by 280

Overall survival results from the POLO trial: A Phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer

Kindler, H. L., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J. O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2022) · Journal of Clinical Oncology

PARP inhibition in cancer therapyPancreatic and Hepatic Oncology Research

Cited by 244

A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

Hoang, D.-T., Dinstag, G., Shulman, E. D., Hermida, L. C., Ben-Zvi, D. S., Elis, E., Caley, K., Sammut, S.-J., Sinha, S., Sinha, N., et al. (2024) · Nature Cancer

AI in cancer detectionRadiomics and Machine Learning in Medical Imaging

Cited by 157

Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials

Javle, M., Shacham-Shmueli, E., Xiao, L., Varadhachary, G., Halpern, N., Fogelman, D., Boursi, B., Uruba, S., Margalit, O., Wolff, R. A., et al. (2021) · JAMA Oncology

PARP inhibition in cancer therapyPancreatic and Hepatic Oncology Research

Cited by 127

LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

Golan, T., Geva, R., Richards, D., Madhusudan, S., Lin, B. K., Wang, H. T., Walgren, R. A., & Stemmer, S. M. (2018) · Journal of Cachexia, Sarcopenia and Muscle

Pancreatic and Hepatic Oncology ResearchNutrition and Health in Aging

Cited by 109

BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

Shaashua, L., Ben-Shmuel, A., Pevsner-Fischer, M., Friedman, G., Levi-Galibov, O., Nandakumar, S., Barki, D., Nevo, R., Brown, L. E., Zhang, W., et al. (2022) · Nature Communications

Pancreatic and Hepatic Oncology ResearchCancer Cells and Metastasis

Cited by 79

The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria

Schultz, C. W., McCarthy, G. A., Nerwal, T., Nevler, A., DuHadaway, J. B., McCoy, M. D., Jiang, W., Brown, S. Z., Goetz, A., Jain, A., et al. (2021) · Molecular Cancer Therapeutics

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 34